Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aptevo Therapeutics (APVO) Gains from Sales and Divestitures (2017 - 2025)

Aptevo Therapeutics' Gains from Sales and Divestitures history spans 9 years, with the latest figure at $26.0 for Q3 2025.

  • For Q3 2025, Gains from Sales and Divestitures fell 99.21% year-over-year to $26.0; the TTM value through Sep 2025 reached $26.0, down 99.21%, while the annual FY2024 figure was $117.0, 99.88% down from the prior year.
  • Gains from Sales and Divestitures for Q3 2025 was $26.0 at Aptevo Therapeutics, down from $72.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $101504.0 in Q4 2023 and bottomed at $26.0 in Q3 2025.
  • The 5-year median for Gains from Sales and Divestitures is $10582.0 (2022), against an average of $24374.9.
  • The largest annual shift saw Gains from Sales and Divestitures skyrocketed 1690.3% in 2022 before it crashed 99.88% in 2024.
  • A 5-year view of Gains from Sales and Divestitures shows it stood at $1000.0 in 2021, then surged by 1690.3% to $17903.0 in 2022, then soared by 466.97% to $101504.0 in 2023, then plummeted by 99.88% to $117.0 in 2024, then crashed by 77.78% to $26.0 in 2025.
  • Per Business Quant, the three most recent readings for APVO's Gains from Sales and Divestitures are $26.0 (Q3 2025), $72.0 (Q1 2025), and $117.0 (Q4 2024).